Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Portfolio Pulse from Nabaparna Bhattacharya
Vaxart, Inc. (NASDAQ: VXRT) has secured a $453 million project award from BARDA to fund a Phase 2b study of its oral COVID-19 vaccine. Additionally, Vaxart announced an equity offering to raise $40 million. Despite initial premarket gains, VXRT shares are trading lower by 7.68%.

June 14, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart has secured a $453 million project award from BARDA to fund a Phase 2b study of its oral COVID-19 vaccine. Additionally, the company announced an equity offering to raise $40 million. Despite initial premarket gains, VXRT shares are trading lower by 7.68%.
The $453 million BARDA award is a significant positive development for Vaxart, providing substantial funding for its COVID-19 vaccine study. However, the announcement of a $40 million equity offering has likely contributed to the short-term decline in share price due to dilution concerns. The overall impact is positive due to the large funding award, but the equity offering has tempered immediate gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100